US EditionOcugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will present its latest advances in gene therapy for blindness diseases at NobleCon21, the annual emerging growth equity conference hosted by Noble Capital Markets, the company announced. Dr. Shankar Musunuri, Ocugen’s chairman, CEO and co-founder, is scheduled to deliver a presentation and fireside chat at 1 p.m. ET on Dec. 3 in Presentation Room 2 at Florida Atlantic University’s Executive Education Co…
Coave Therapeutics Unveils Lead Gene Therapy Program, CoTx-101, for Retinal Vascular Diseases
Coave Therapeutics announced the nomination of its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, such as wet age-related macular degeneration and diabetic macular edema. With the use of Coave’s proprietary suprachoroidal vector (coAAV-SCS), CoTx-101 aims to deliver durable vision gains via an in-office procedure. Coave presented data in October at the European Society of Gene and Cell Therapy Congress 2025 …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
